Carfilzomib has been evaluated in numerous clinical trials ranging from Phase 1 dose-finding studies to Phase 4 post-marketing research, primarily targeting relapsed or refractory multiple myeloma alongside non-Hodgkin lymphomas, Waldenström macroglobulinemia, chronic graft-versus-host disease, and kidney transplantation desensitization. Sponsored by academic medical centers and pharmaceutical leaders including Amgen, Bristol-Myers Squibb, and Pfizer, these investigations encompass completed, active non-recruiting, and currently recruiting protocols.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06892522 | RECRUITING | Multiple Myeloma |
AbbVie |
2025-06-30 | PHASE1; PHASE2 |
| NCT07728188 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma |
AbbVie |
2026-11-30 | PHASE3 |
| NCT07605416 | RECRUITING | Plasma Cell Leukemia |
National Cancer Institute (NCI) |
2027-04-20 | PHASE2 |
| NCT04513639 | RECRUITING | Multiple Myeloma |
Oslo University Hospital |
2020-08-27 | PHASE2; PHASE3 |
| NCT07227311 | RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2026-04-15 | PHASE2 |
| NCT07715903 | NOT_YET_RECRUITING | Colorectal Neoplasms; Neoplasms; Intrahepatic Cholangiocarcinoma; Adrenocortical Carcinoma; Metastasis, Neoplasm |
National Cancer Institute (NCI) |
2026-09-09 | PHASE1 |
| NCT03948035 | ACTIVE_NOT_RECRUITING | Newly Diagnosed Multiple Myeloma |
Wuerzburg University Hospital |
2018-08-28 | PHASE3 |
| NCT06536413 | RECRUITING | Multiple Myeloma |
The Methodist Hospital Research Institute |
2024-07-29 | PHASE1; PHASE2 |
| NCT07222761 | RECRUITING | Relapsed and/or Refractory Multiple Myeloma (RRMM) |
Regeneron Pharmaceuticals |
2026-01-02 | PHASE3 |
| NCT04822337 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Wake Forest University Health Sciences |
2021-05-19 | PHASE1; PHASE2 |
| NCT07463807 | RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2027-04-12 | PHASE1; PHASE2 |
| NCT05896228 | RECRUITING | Refractory Multiple Myeloma; Relapsed Multiple Myeloma |
Benjamin T Diamond, MD |
2024-02-20 | PHASE2 |
| NCT07348393 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Assistance Publique - Hôpitaux de Paris |
2026-02 | PHASE2 |
| NCT05438043 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2022-12-15 | PHASE3 |
| NCT07709884 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma; T(11;14); Sotoclax; Carfilzomib |
The First Affiliated Hospital of Soochow University |
2026-07-01 | PHASE4 |
| NCT05669989 | ENROLLING_BY_INVITATION | Plasma Cell Myeloma |
Sanofi |
2023-04-05 | PHASE2 |
| NCT07555938 | RECRUITING | Multiple Myeloma |
Hoffmann-La Roche |
2026-06-23 | PHASE3 |
| NCT05434689 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Alabama at Birmingham |
2023-01-18 | PHASE1; PHASE2 |
| NCT05789303 | RECRUITING | Multiple Myeloma; Relapse Multiple Myeloma |
University of Chicago |
2023-05-30 | PHASE2 |
| NCT06413498 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Kite, A Gilead Company |
2024-08-23 | PHASE3 |
| NCT07391657 | RECRUITING | Relapsed Refractory Multiple Myeloma |
AstraZeneca |
2026-02-23 | PHASE3 |
| NCT04263480 | ACTIVE_NOT_RECRUITING | Waldenstrom Macroglobulinemia |
Christian Buske |
2021-08-18 | PHASE2 |
| NCT05137054 | RECRUITING | Multiple Myeloma |
Regeneron Pharmaceuticals |
2022-08-17 | PHASE1 |
| NCT06879379 | RECRUITING | Multiple Myeloma, Newly Diagnosed |
Peking University People's Hospital |
2025-03 | PHASE2; PHASE3 |
| NCT06948084 | NOT_YET_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2026-08-26 | PHASE2 |
| NCT07082270 | WITHDRAWN | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Roswell Park Cancer Institute |
2026-04-01 | PHASE1 |
| NCT07652879 | RECRUITING | POEMS Syndrome |
Shanghai Changzheng Hospital |
2026-06-15 | PHASE2 |
| NCT05651932 | RECRUITING | Multiple Myeloma; Myeloma; Myeloma Multiple |
K36 Therapeutics, Inc. |
2023-02-22 | PHASE1 |
| NCT06615479 | RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2025-03-12 | PHASE3 |
| NCT06158841 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2024-05-19 | PHASE3 |
| NCT06409702 | RECRUITING | Newly Diagnosed; High Risk; MRD; Multiple Myeloma |
The First Affiliated Hospital of Soochow University |
2024-06-12 | PHASE4 |
| NCT02659293 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Chicago |
2016-04-26 | PHASE3 |
| NCT04850599 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
OHSU Knight Cancer Institute |
2022-06-14 | PHASE2 |
| NCT07479979 | RECRUITING | Relapse Multiple Myeloma; Refractory Multiple Myeloma |
Natalie Callander |
2026-05-21 | PHASE1; PHASE2 |
| NCT03556332 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2018-07-02 | PHASE2 |
| NCT06918990 | RECRUITING | Kidney Transplant Rejection |
National Institute of Allergy and Infectious Diseases (NIAID) |
2026-05-27 | PHASE1 |
| NCT05909826 | NOT_YET_RECRUITING | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Dong-A University Hospital |
2023-07-01 | PHASE2 |
| NCT02899052 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
AbbVie |
2017-01-19 | PHASE2 |
| NCT01297764 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Hackensack Meridian Health |
2011-04 | PHASE1; PHASE2 |
| NCT06627751 | RECRUITING | Extramedullary Disease in Multiple Myeloma; Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Roswell Park Cancer Institute |
2025-05-01 | PHASE2 |
| NCT04176718 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse; Relapse |
Andrew Yee, MD |
2020-05-18 | PHASE2 |
| NCT06622005 | RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Roswell Park Cancer Institute |
2025-04-10 | PHASE1 |
| NCT02343042 | RECRUITING | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-10 | PHASE1; PHASE2 |
| NCT05199311 | SUSPENDED | Multiple Myeloma |
Hackensack Meridian Health |
2022-05-13 | PHASE1; PHASE2 |
| NCT05017545 | ACTIVE_NOT_RECRUITING | Highly Sensitized Prospective Kidney Transplant Recipients |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-12-28 | PHASE1; PHASE2 |
| NCT04268498 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Miami |
2020-02-11 | PHASE2 |
| NCT04661137 | SUSPENDED | Multiple Myeloma |
Hackensack Meridian Health |
2021-03-16 | PHASE2 |
| NCT06356571 | RECRUITING | Plasma Cell Myeloma Refractory |
Sanofi |
2025-03-17 | PHASE2 |
| NCT04883242 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
University of Washington |
2021-07-29 | PHASE2 |
| NCT01863550 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
ECOG-ACRIN Cancer Research Group |
2013-12-06 | PHASE3 |
| NCT03729804 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Chicago |
2019-05-07 | PHASE3 |
| NCT03989414 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Celgene |
2019-09-30 | PHASE1; PHASE2 |
| NCT06249282 | RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
City of Hope Medical Center |
2024-04-24 | PHASE1 |
| NCT04973605 | RECRUITING | Relapsed/Refractory Multiple Myeloma |
BeOne Medicines |
2021-09-16 | PHASE1; PHASE2 |
| NCT06140966 | RECRUITING | Multiple Myeloma; Primary Plasma Cell Leukemia; Extramedullary Multiple Myeloma |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2023-10-20 | PHASE2 |
| NCT03004287 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Arkansas |
2017-07-01 | PHASE2 |
| NCT03909412 | RECRUITING | Multiple Myeloma |
Hackensack Meridian Health |
2019-10-08 | PHASE1 |
| NCT04933539 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
National Cancer Institute (NCI) |
2022-10-31 | PHASE2 |
| NCT06152575 | RECRUITING | Multiple Myeloma |
Pfizer |
2024-02-08 | PHASE3 |
| NCT05552976 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Bristol-Myers Squibb |
2023-01-10 | PHASE3 |
| NCT03500445 | ACTIVE_NOT_RECRUITING | Myeloma; Multiple Myeloma |
University of Chicago |
2019-02-13 | PHASE2 |
| NCT06793475 | RECRUITING | Extramedullary Multiple Myeloma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-04-09 | |
| NCT04764942 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
Mayo Clinic |
2021-05-06 | PHASE1; PHASE2 |
| NCT03104842 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Universitätsklinikum Hamburg-Eppendorf |
2017-08-15 | PHASE2 |
| NCT03651128 | COMPLETED | Multiple Myeloma |
Celgene |
2019-04-16 | PHASE3 |
| NCT05675449 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Pfizer |
2022-12-14 | PHASE1 |
| NCT05497804 | ACTIVE_NOT_RECRUITING | ISS Stage III Plasma Cell Myeloma; Multiple Myeloma |
Mayo Clinic |
2022-09-22 | PHASE2 |
| NCT04096066 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; New Diagnosis Tumor |
Fondazione EMN Italy Onlus |
2019-07-01 | PHASE3 |
| NCT02332850 | COMPLETED | Multiple Myeloma |
Thomas Martin, MD |
2015-01-21 | PHASE1 |
| NCT05704049 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Multiple Myeloma |
Sanofi |
2023-04-05 | PHASE2 |
| NCT06232707 | WITHDRAWN | Multiple Myeloma |
Celgene |
2024-05-03 | PHASE3 |
| NCT01665794 | COMPLETED | Multiple Myeloma |
University of Chicago |
2012-08-13 | PHASE1; PHASE2 |
| NCT05572515 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Janssen Research & Development, LLC |
2023-03-29 | PHASE3 |
| NCT02199665 | COMPLETED | Refractory Multiple Myeloma |
University of Chicago |
2014-06-12 | PHASE1 |
| NCT04483739 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
European Myeloma Network B.V. |
2020-09-25 | PHASE3 |
| NCT06055075 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Hoffmann-La Roche |
2023-12-12 | PHASE1; PHASE2 |
| NCT03756896 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Emory University |
2019-01-25 | PHASE2 |
| NCT03290950 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2017-09-25 | PHASE2 |
| NCT04287855 | UNKNOWN | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Poitiers University Hospital |
2020-08-28 | PHASE2 |
| NCT05050097 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-09-22 | PHASE1 |
| NCT05675319 | TERMINATED | Multiple Myeloma |
Universitätsklinikum Hamburg-Eppendorf |
2023-03-03 | PHASE3 |
| NCT04813653 | COMPLETED | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Tel-Aviv Sourasky Medical Center |
2021-04-18 | PHASE1 |
| NCT04288765 | WITHDRAWN | Multiple Myeloma |
Grupo Cooperativo de Hemopatías Malignas |
2020-03-01 | PHASE3 |
| NCT03336073 | UNKNOWN | Multiple Myeloma |
PETHEMA Foundation |
2017-12-18 | PHASE2 |
| NCT05060627 | ACTIVE_NOT_RECRUITING | Relapsed Multiple Myeloma |
PETHEMA Foundation |
2021-12-20 | PHASE1; PHASE2 |
| NCT02937571 | COMPLETED | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2016-10 | PHASE1; PHASE2 |
| NCT04756401 | ACTIVE_NOT_RECRUITING | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Academic and Community Cancer Research United |
2022-12-08 | PHASE2 |
| NCT04925193 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse |
University of Colorado, Denver |
2021-11-18 | PHASE2 |
| NCT03673826 | ACTIVE_NOT_RECRUITING | Smouldering Myeloma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2018-11-19 | PHASE2 |
| NCT03031730 | TERMINATED | Plasmacytoma; Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2018-06-14 | PHASE1 |
| NCT03530683 | TERMINATED | Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma |
Pfizer |
2018-05-14 | PHASE1 |
| NCT05509374 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2021-10-28 | PHASE2 |
| NCT02303821 | COMPLETED | Acute Lymphoblastic Leukemia (ALL) |
Amgen |
2015-02-16 | PHASE1 |
| NCT05556616 | TERMINATED | Multiple Myeloma |
Teva Branded Pharmaceutical Products R&D LLC |
2023-01-12 | PHASE1 |
| NCT02773030 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Celgene |
2016-10-14 | PHASE1; PHASE2 |
| NCT05497102 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2021-11-08 | PHASE2 |
| NCT04892446 | TERMINATED | Multiple Myeloma |
Gilead Sciences |
2021-11-09 | PHASE2 |
| NCT02891811 | COMPLETED | Multiple Myeloma |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2017-03-10 | PHASE2 |
| NCT03815279 | ENROLLING_BY_INVITATION | Multiple Myeloma; Smoldering Multiple Myeloma |
Landspitali University Hospital |
2019-06-24 | PHASE2 |
| NCT03798678 | ACTIVE_NOT_RECRUITING | Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2019-07-08 | PHASE1 |
| NCT03289299 | ACTIVE_NOT_RECRUITING | Smoldering Multiple Myeloma |
International Myeloma Foundation |
2018-05-25 | PHASE2 |
| NCT03155100 | COMPLETED | Multiple Myeloma in Relapse |
Raija Silvennoinen |
2017-08-07 | PHASE2 |
| NCT03742297 | ACTIVE_NOT_RECRUITING | Newly Diagnosed Multiple Myeloma |
PETHEMA Foundation |
2018-10-22 | PHASE3 |
| NCT04113018 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Wake Forest University Health Sciences |
2020-01-10 | PHASE2 |
| NCT03859427 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Amgen |
2019-05-08 | PHASE3 |
| NCT03934684 | COMPLETED | Relapsed Refractory Multiple Myeloma |
Amgen |
2019-09-16 | PHASE4 |
| NCT05184595 | UNKNOWN | Multiple Myeloma |
Central Hospital, Nancy, France |
2022-01-01 | |
| NCT02341014 | COMPLETED | T-cell Lymphomas; Relapsed or Refractory |
Memorial Sloan Kettering Cancer Center |
2015-01-02 | PHASE1; PHASE2 |
| NCT05552976 | Recruiting | Relapsed or Refractory Multiple Myeloma |
Bristol-Myers Squibb |
2023-01-10 | Phase 3 |
| NCT05675449 | Recruiting | Multiple Myeloma |
Pfizer |
2022-12-14 | Phase 1 |
| NCT04191616 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Amgen |
2020-08-06 | PHASE2 |
| NCT03773107 | COMPLETED | Multiple Myeloma |
Wake Forest University Health Sciences |
2019-01-03 | PHASE1; PHASE2 |
| NCT03795597 | UNKNOWN | Multiple Myeloma |
Loyola University |
2019-05-22 | PHASE1; PHASE2 |
| NCT03871829 | TERMINATED | Multiple Myeloma |
Janssen Research & Development, LLC |
2019-05-31 | PHASE2 |
| NCT03605719 | COMPLETED | Recurrent Plasma Cell Myeloma |
Emory University |
2018-10-24 | PHASE1 |
| NCT03432741 | TERMINATED | Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7 |
Mayo Clinic |
2018-03-27 | PHASE1 |
| NCT04430894 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2020-07-10 | PHASE2 |
| NCT04895410 | TERMINATED | Multiple Myeloma |
AbbVie |
2022-01-17 | PHASE1 |
| NCT01572480 | COMPLETED | Multiple Myeloma |
National Cancer Institute (NCI) |
2012-05-29 | PHASE2 |
| NCT03606577 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Nantes University Hospital |
2019-07-30 | PHASE2 |
| NCT03375567 | COMPLETED | Multiple Myeloma |
Yale University |
2018-06-04 | |
| NCT03275285 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2017-10-25 | PHASE3 |
| NCT04163107 | COMPLETED | Multiple Myeloma |
Norwegian University of Science and Technology |
2020-01-07 | PHASE1 |
| NCT01554852 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2010-05 | PHASE3 |
| NCT03314636 | ACTIVE_NOT_RECRUITING | Myeloma |
Oslo University Hospital |
2018-03-16 | PHASE2 |
| NCT02969837 | COMPLETED | Multiple Myeloma |
University of Chicago |
2017-07-10 | PHASE2 |
| NCT05041933 | Unknown status | Hematological Diseases |
University Hospital Limoges |
2021-09-15 | -- |
| NCT02512926 | COMPLETED | Relapsed Solid Tumors; Refractory Solid Tumors; Relapsed Leukemia; Refractory Leukemia |
Stanford University |
2016-02-16 | PHASE1 |
| NCT04065789 | COMPLETED | Myeloma Multiple; Myeloma, Plasma-Cell; Myeloma-Multiple; Plasma Cell Myeloma |
Tel-Aviv Sourasky Medical Center |
2018-05-02 | PHASE2 |
| NCT02073097 | COMPLETED | Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma |
Case Comprehensive Cancer Center |
2015-01-28 | PHASE1; PHASE2 |
| NCT03361306 | COMPLETED | Multiple Myeloma |
Wake Forest University Health Sciences |
2018-01-09 | PHASE2 |
| NCT02442648 | UNKNOWN | Transplants and Implants |
E. Steve Woodle |
2014-12 | PHASE1 |
| NCT03416374 | COMPLETED | Relapsed and/or Refractory Multiple Myeloma |
Takeda |
2018-02-18 | PHASE4 |
| NCT02318784 | COMPLETED | Neuroendocrine Cancer |
SCRI Development Innovations, LLC |
2015-07-15 | PHASE2 |
| NCT02101944 | COMPLETED | Anemia; Recurrent Multiple Myeloma; Refractory Multiple Myeloma |
National Cancer Institute (NCI) |
2014-12-09 | PHASE1 |
| NCT03201250 | TERMINATED | Multiple Myeloma; Refractory Multiple Myeloma; Relapsed/Refractory Multiple Myeloma |
University of Nebraska |
2018-02-21 | PHASE1; PHASE2 |
| NCT02187133 | COMPLETED | Lymphoma, Non-Hodgkin; Lymphoma |
University of California, San Francisco |
2015-05-05 | PHASE1 |
| NCT03256045 | TERMINATED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
University of Washington |
2018-02-08 | PHASE2 |
| NCT02756663 | WITHDRAWN | Multiple Myeloma |
Novartis Pharmaceuticals |
2016-12 | PHASE2 |
| NCT02095834 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2014-04-24 | PHASE1 |
| NCT03891355 | UNKNOWN | Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2019-09-30 | PHASE2 |
| NCT01496118 | COMPLETED | Multiple Myeloma |
SCRI Development Innovations, LLC |
2011-12 | PHASE1; PHASE2 |
| NCT02474927 | COMPLETED | Lung Transplant Rejection |
John F. McDyer, MD |
2015-11-01 | PHASE2 |
| NCT02217163 | COMPLETED | Multiple Myeloma |
Singapore General Hospital |
2014-10 | PHASE2 |
| NCT02294357 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2014-12 | PHASE2 |
| NCT02802163 | WITHDRAWN | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2017-06 | PHASE1; PHASE2 |
| NCT03412565 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2018-04-26 | PHASE2 |
| NCT03805178 | WITHDRAWN | Lung Transplant Rejection; Antibody-mediated Rejection |
Duke University |
2019-05-01 | PHASE2 |
| NCT03141203 | COMPLETED | Peripheral T Cell Lymphoma |
University of Birmingham |
2015-07-13 | PHASE1; PHASE2 |
| NCT01464034 | TERMINATED | Multiple Myeloma |
Criterium, Inc. |
2011-11 | PHASE1; PHASE2 |
| NCT02867618 | TERMINATED | Hodgkin Disease; Lymphoma, Non-hodgkin |
Columbia University |
2016-10-16 | PHASE1; PHASE2 |
| NCT01959698 | ACTIVE_NOT_RECRUITING | CD20 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Stage I Diffuse Large B-Cell Lymphoma; Stage II Diffuse Large B-Cell Lymphoma; Stage III Diffuse Large B-Cell Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma |
Roswell Park Cancer Institute |
2014-04-17 | PHASE1 |
| NCT02036502 | TERMINATED | Multiple Myeloma |
Merck Sharp & Dohme LLC |
2014-02-14 | PHASE1 |
| NCT03512353 | TERMINATED | Relapsed or Refractory Multiple Myeloma |
Amgen |
2018-07-05 | PHASE2 |
| NCT02405364 | COMPLETED | Multiple Myeloma |
University Hospital, Toulouse |
2014-02 | PHASE2 |
| NCT01301807 | COMPLETED | Non-Secretory Plasma Cell Myeloma; Plasmacytosis; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2011-07-28 | PHASE1 |
| NCT02315716 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University College, London |
2015-06-16 | PHASE2 |
| NCT02335983 | COMPLETED | Multiple Myeloma |
Amgen |
2015-04-30 | PHASE1 |
| NCT03104270 | TERMINATED | Multiple Myeloma |
Oncotherapeutics |
2017-03-13 | PHASE2 |
| NCT02545907 | COMPLETED | Amyloidosis |
University College, London |
2017-09-14 | PHASE1; PHASE2 |
| NCT02336815 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-05-26 | PHASE2 |
| NCT03158688 | COMPLETED | Relapsed Multiple Myeloma; Refractory Multiple Myeloma |
Amgen |
2017-06-13 | PHASE3 |
| NCT02597062 | COMPLETED | Multiple Myeloma |
Canadian Cancer Trials Group |
2016-07-05 | PHASE2 |
| NCT03140943 | UNKNOWN | Relapsed and/or Refractory Multiple Myeloma |
National University Hospital, Singapore |
2017-09-13 | PHASE2 |
| NCT01372540 | COMPLETED | Plasma Cell Leukemia; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2012-02-24 | PHASE1 |
| NCT02002598 | TERMINATED | Multiple Myeloma |
Suzanne Lentzsch, MD |
2013-11 | PHASE1; PHASE2 |
| NCT01962792 | COMPLETED | Multiple Myeloma |
Pharmacyclics LLC. |
2013-12 | PHASE1; PHASE2 |
| NCT02265510 | TERMINATED | Solid Tumors; Advanced Malignancies; Metastatic Cancer |
Incyte Corporation |
2014-09-10 | PHASE1; PHASE2 |
| NCT01998971 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2014-02-18 | PHASE1 |
| NCT01775930 | COMPLETED | Kidney Cancer |
M.D. Anderson Cancer Center |
2013-10 | PHASE2 |
| NCT01941316 | COMPLETED | Small Cell Lung Carcinoma; Non Small Cell Lung Carcinoma; Irinotecan Sensitive Cancers |
Cancer Research and Biostatistics Clinical Trials Consortium |
2013-11 | PHASE1; PHASE2 |
| NCT03269552 | TERMINATED | Marginal Zone Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory Marginal Zone Lymphoma; Refractory Waldenstrom Macroglobulinemia; Waldenstrom Macroglobulinemia |
University of Washington |
2017-12-18 | PHASE2 |
| NCT02148913 | COMPLETED | Multiple Myeloma |
Corewell Health West |
2014-06 | PHASE1 |
| NCT01792102 | UNKNOWN | Multiple Myeloma |
Oncotherapeutics |
2013-04 | PHASE1; PHASE2 |
| NCT02145403 | COMPLETED | Hematologic Malignancies; Relapse; Graft-Versus-Host Disease |
University of Michigan Rogel Cancer Center |
2014-10 | PHASE1; PHASE2 |
| NCT03029234 | COMPLETED | Relapsed and Refractory Multiple Myeloma |
Amgen |
2017-03-31 | PHASE3 |
| NCT01729104 | TERMINATED | Lymphoma |
M.D. Anderson Cancer Center |
2013-04-25 | PHASE1 |
| NCT02114502 | WITHDRAWN | Myeloma |
M.D. Anderson Cancer Center |
2014-09 | PHASE2 |
| NCT02415413 | ACTIVE_NOT_RECRUITING | Smoldering Multiple Myeloma |
PETHEMA Foundation |
2015-05 | PHASE2 |
| NCT02269085 | TERMINATED | Lymphoma |
M.D. Anderson Cancer Center |
2015-04-20 | PHASE1 |
| NCT02572492 | UNKNOWN | Multiple Myeloma |
Henrik Gregersen |
2015-01 | PHASE2 |
| NCT01816971 | COMPLETED | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
University of Chicago |
2013-01 | PHASE2 |
| NCT02491359 | COMPLETED | Chronic Graft Versus Host Disease |
Fred Hutchinson Cancer Center |
2015-11-12 | PHASE2 |
| NCT02206425 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2014-09 | PHASE1; PHASE2 |
| NCT01246063 | COMPLETED | Multiple Myeloma |
Washington University School of Medicine |
2012-05-14 | PHASE1; PHASE2 |
| NCT02042950 | TERMINATED | Lymphoma |
M.D. Anderson Cancer Center |
2014-07-14 | PHASE2 |
| NCT02293109 | COMPLETED | Contiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia |
Mehrdad Abedi, MD |
2015-12-17 | PHASE1 |
| NCT01903811 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
SWOG Cancer Research Network |
2013-10 | PHASE2 |
| NCT01690143 | COMPLETED | Multiple Myeloma |
University of Alabama at Birmingham |
2012-05 | PHASE1; PHASE2 |
| NCT01991301 | UNKNOWN | Graft-versus-host Disease |
Sheba Medical Center |
2014-11 | PHASE1 |
| NCT01842308 | COMPLETED | DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2013-06-04 | PHASE1; PHASE2 |
| NCT01926665 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
2014-06-17 | PHASE1 |
| NCT02412878 | COMPLETED | Multiple Myeloma |
Amgen |
2015-09-09 | PHASE3 |
| NCT02047253 | COMPLETED | Metastatic Castration-resistant Prostate Cancer |
University of Alabama at Birmingham |
2014-04 | PHASE2 |
| NCT02628704 | WITHDRAWN | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-12 | PHASE2 |
| NCT00884312 | COMPLETED | Multiple Myeloma; Solid Tumors |
Amgen |
2009-04-09 | PHASE2 |
| NCT02142530 | COMPLETED | Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Peripheral T-cell Lymphoma |
Massachusetts General Hospital |
2014-10 | PHASE1 |
| NCT01789242 | COMPLETED | Amyloidosis; Systemic Light Chain Amyloidosis |
Criterium, Inc. |
2013-02 | PHASE1 |
| NCT02257476 | COMPLETED | Neoplasms; Malignancies |
Emory University |
2014-08 | PHASE1 |
| NCT01738594 | TERMINATED | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary Syndrome; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome |
Northwestern University |
2013-03-22 | PHASE1 |
| NCT02203643 | COMPLETED | MULTIPLE MYELOMA (MM) |
Mario Boccadoro |
2015-02 | PHASE2 |
| NCT01470196 | COMPLETED | Waldenstrom's Macroglobulinemia |
Dana-Farber Cancer Institute |
2011-10 | PHASE2 |
| NCT01987232 | COMPLETED | Extensive-Stage Small-Cell Lung Cancer |
Amgen |
2013-11-05 | PHASE1; PHASE2 |
| NCT01677858 | COMPLETED | Multiple Myeloma |
Amgen |
2012-07-04 | PHASE1; PHASE2 |
| NCT02302495 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2014-01-08 | PHASE2 |
| NCT01818752 | COMPLETED | Multiple Myeloma |
Amgen |
2013-07-08 | PHASE3 |
| NCT01402284 | COMPLETED | Multiple Myeloma |
National Cancer Institute (NCI) |
2011-07-21 | PHASE2 |
| NCT01559935 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2012-04-19 | PHASE2 |
| NCT01775553 | COMPLETED | Relapse Multiple Myeloma; Refractory Multiple Myeloma |
Ajai Chari |
2013-09 | PHASE2 |
| NCT01204164 | COMPLETED | AML; ALL; Blast Crisis; MDS; Multiple Myeloma |
Tragara Pharmaceuticals, Inc. |
2010-08 | PHASE1 |
| NCT01980589 | COMPLETED | Multiple Myeloma |
Amgen |
2013-08 | PHASE1 |
| NCT01549431 | COMPLETED | Multiple Myeloma |
Emory University |
2012-01 | PHASE1 |
| NCT01989325 | COMPLETED | Advanced Multiple Myeloma |
Pfizer |
2013-11 | PHASE2 |
| NCT01351623 | COMPLETED | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2011-05-09 | PHASE2 |
| NCT02020941 | TERMINATED | Refractory Multiple Myeloma |
Attaya Suvannasankha |
2013-09 | PHASE2 |
| NCT02235740 | TERMINATED | Cancer |
Novartis |
2014-11 | PHASE1 |
| NCT02056756 | COMPLETED | Multiple Myeloma |
Stichting European Myeloma Network |
2014-04 | PHASE1; PHASE2 |
| NCT01949545 | COMPLETED | Solid Tumors; Hematologic Malignancies; Hepatic Impairment |
Amgen |
2013-10 | PHASE1 |
| NCT01660750 | COMPLETED | Multiple Myeloma |
Criterium, Inc. |
2013-01 | PHASE1 |
| NCT02185820 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2014-06 | PHASE1; PHASE2 |
| NCT02204241 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2014-06 | PHASE1; PHASE2 |
| NCT01336920 | COMPLETED | Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma |
University of Nebraska |
2011-06-21 | PHASE1 |
| NCT01949532 | COMPLETED | Relapsed Multiple Myeloma; End-stage Renal Disease |
Amgen |
2014-01 | PHASE1 |
| NCT01568866 | COMPLETED | Multiple Myeloma |
Amgen |
2012-06-20 | PHASE3 |
| NCT01969565 | TERMINATED | Multiple Myeloma |
Emory University |
2013-08 | PHASE2 |
| NCT00531284 | COMPLETED | Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma; Lymphoma |
Amgen |
2007-09 | PHASE1; PHASE2 |
| NCT01813227 | COMPLETED | Waldenstrom Macroglobulinemia |
Hackensack Meridian Health |
2013-04 | PHASE2 |
| NCT01812720 | WITHDRAWN | Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Mayo Clinic |
2013-08 | PHASE2 |
| NCT01137747 | COMPLETED | Leukemia |
Washington University School of Medicine |
2010-10 | PHASE1 |
| NCT01212380 | COMPLETED | B-cell Chronic Lymphocytic Leukemia; Hematopoietic/Lymphoid Cancer; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia |
Ohio State University Comprehensive Cancer Center |
2010-10 | PHASE1 |
| NCT01302392 | COMPLETED | Multiple Myeloma |
Amgen |
2010-09 | PHASE3 |
| NCT01080391 | COMPLETED | Relapsed Multiple Myeloma |
Amgen |
2010-07-14 | PHASE3 |
| NCT01365559 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2011-05-02 | PHASE1; PHASE2 |
| NCT01057225 | COMPLETED | Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Mayo Clinic |
2010-03 | PHASE1; PHASE2 |
| NCT01537861 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2012-06 | EARLY_PHASE1 |
| NCT01279694 | COMPLETED | Myeloma |
Nantes University Hospital |
2010-10 | PHASE1; PHASE2 |
| NCT01658904 | TERMINATED | Multiple Myeloma; Leukemia, Plasma Cell |
National Cancer Institute (NCI) |
2012-07 | PHASE1; PHASE2 |
| NCT01857115 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2013-04 | PHASE1; PHASE2 |
| NCT01276717 | COMPLETED | Lymphoma |
University of Rochester |
2011-01 | PHASE1 |
| NCT00603447 | COMPLETED | Relapsed Multiple Myeloma |
Amgen |
2008-05 | PHASE1 |
| NCT00530816 | COMPLETED | Multiple Myeloma |
Amgen |
2007-09 | PHASE2 |
| NCT00721734 | COMPLETED | Multiple Myeloma; Renal Insufficiency |
Amgen |
2008-11 | PHASE2 |
| NCT01346787 | COMPLETED | Multiple Myeloma |
European Myeloma Network B.V. |
2011-07 | PHASE2 |
| NCT01029054 | COMPLETED | Multiple Myeloma |
University of Michigan Rogel Cancer Center |
2009-09 | PHASE1; PHASE2 |
| NCT00511238 | COMPLETED | Multiple Myeloma |
Amgen |
2007-08 | PHASE2 |
| NCT00150462 | COMPLETED | Waldenstrom's Macroglobulinemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma |
Amgen |
2005-09 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-07-21)
Check the
PR-171 (Carfilzomib)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- PR-171 (Carfilzomib) Mechanism of Action: Proteasome Inhibition in Plasma Cell Research
- PR-171 (Carfilzomib): Selectivity & Specificity
- PR-171 (Carfilzomib) Working Concentration | Cell Culture | Treatment
- PR-171 (Carfilzomib) Solubility in DMSO
- PR-171 (Carfilzomib) Stock Solution
- PR-171 (Carfilzomib) Storage
- PR-171 (Carfilzomib) Stability
- PR-171 (Carfilzomib) Combination Database
- PR-171 (Carfilzomib) Molecular Weight
- PR-171 (Carfilzomib) SMILES
- PR-171 (Carfilzomib) CAS Number
- PR-171 (Carfilzomib) Chemical Structure (2D and 3D)
- PR-171 (Carfilzomib) IC50 for Cell-based and Cell-free Assays
- PR-171 (Carfilzomib) Sigma (ADV412110416)? Try a better option.
- PR-171 (Carfilzomib) MedChemExpress (HY-10455)? Try a better option.
- PR-171 (Carfilzomib) Cayman (17554)? Try a better option.
- PR-171 (Carfilzomib) APExBIO (A1933)? Try a better option.
- PR-171 (Carfilzomib) Tocris (7188)? Try a better option.
- PR-171 (Carfilzomib) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.